Physician profile
Todd P Thompson
NPI 1346241965
$4,204.33
in general payments reported to CMS, 2019-2025
25 companies · $32.81 in 2025
The $32.81 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,303 · 2020: $39.53 · 2021: $214 · 2022: $575 · 2023: $402 · 2024: $638 · 2025: $32.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,553.30 | 2019-2025 | Clareon, Argos, Unity |
| Sun Pharmaceutical Industries INC. | $196.23 | 2022-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $181.53 | 2019-2023 | Tecnis Iol |
| Allergan, INC. | $154.38 | 2019-2022 | |
| Portola Pharmaceuticals, LLC | $126.13 | 2019 | |
| Abbvie INC. | $108.00 | 2023-2024 | Durysta |
| Biotissue Holdings INC. | $106.33 | 2023-2024 | |
| Omeros Corporation | $88.82 | 2019-2021 | |
| Horizon Therapeutics Plc | $73.11 | 2021-2023 | Tepezza |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $59.25 | 2024 | Xdemvy |
| Immunogen, INC. | $58.62 | 2023 | Elahere |
| Amgen INC. | $57.96 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $53.69 | 2021-2024 | Dextenza |
| Harrow Eye, LLC | $51.01 | 2024 | Iheezo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.82 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $45.99 | 2024 | Miebo, Xiidra |
| Kala Pharmaceuticals, INC. | $38.10 | 2021-2022 | |
| Sight Sciences, INC. | $36.27 | 2019-2022 | |
| Ethicon US, LLC | $31.46 | 2021 | |
| Eyevance Pharmaceuticals LLC | $19.83 | 2021 | |
| Oyster Point Pharma, INC. | $18.16 | 2022 | |
| Glaukos Corporation | $14.81 | 2024 | Idose |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.09 | 2020 | |
| New World Medical,INC. | $5.73 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.